Dynavax Technologies Corp... (DVAX)
NASDAQ: DVAX
· Real-Time Price · USD
10.13
0.22 (2.22%)
At close: Sep 03, 2025, 3:59 PM
2.22% (1D)
| Bid | 9.94 |
| Market Cap | 1.19B |
| Revenue (ttm) | 316.27M |
| Net Income (ttm) | -52.73M |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -22.51 |
| Forward PE | 20.65 |
| Analyst | Buy |
| Ask | 10.18 |
| Volume | 1,634,105 |
| Avg. Volume (20D) | 1,667,398 |
| Open | 9.84 |
| Previous Close | 9.91 |
| Day's Range | 9.83 - 10.18 |
| 52-Week Range | 9.22 - 14.63 |
| Beta | 1.09 |
About DVAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DVAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Dynavax Technologies Corporation is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-1.05%
Shares of vaccine companies are trading lower foll...
Unlock content with
Pro Subscription
2 weeks ago
+5.09%
Dynavax Technologies shares are trading higher after the company announced its shingles vaccine candidate Z-1018 has shown efficacy in its Phase 1/2 trial.
3 weeks ago · seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call TranscriptDynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Sen...
3 weeks ago · fool.com
Dynavax (DVAX) Q2 Revenue Jumps 29%Dynavax (DVAX) Q2 Revenue Jumps 29%
